-

Bruker Makes Routine Magnetic Resonance Spectroscopy More Broadly Accessible for Chemical Analysis Outside Central Labs

At ENC 2021, Bruker Showcases Enhanced Benchtop Fourier 80™ FT-NMR, Affordable AvanceCore™ 400 NMR, and Versatile Benchtop Magnettech™ ESR 5000

BILLERICA, Mass.--(BUSINESS WIRE)--Just prior to the 2021 Experimental Nuclear Magnetic Resonance Conference (www.enc-conference.org), Bruker Corporation (Nasdaq: BRKR) is making chemical analysis by magnetic resonance spectroscopy more broadly accessible beyond the central lab. Bruker’s new magnetic resonance systems are intended for pharma, chemical and food research and analysis, as well as for teaching and chemistry research in any academic lab, university department or college.

Specifically, Bruker announces the US/Canadian launch of the convenient, permanent-magnet Fourier™ 80 system, a next-generation, high-performance 80 MHz Fourier Transform Nuclear Magnetic Resonance (FT-NMR) benchtop spectrometer for multinuclear gradient spectroscopy, and with industry-standard automation options. The Fourier 80, together with the AvanceCore 400, an affordable 400 MHz NMR, plus the versatile Bruker Magnettech ESR 5000 benchtop EPR (Electron Paramagnetic Resonance) broaden the magnetic resonance analytical solutions for academic, pharma and chemical industry - beyond central labs.

The permanent-magnet based Fourier 80, which does not require cryogens, has been meticulously designed for highest data quality and stability at 80 MHz, with excellent lineshape, resolution and sensitivity in homonuclear 1H or heteronuclear gradient-spectroscopy FT-NMR experiments. The latest developments include a heteronuclear 1H/31P configuration for food analysis, biological or medicinal research applications, organometallic chemistry and more.

As previously announced, the Fourier 80 offers even greater sensitivity and 20% improved resolution performance. It can be operated by the easy-to-use GoScan™ software for NMR beginners, or by Bruker's TopSpin™ NMR software with the extensive TopSpin library of 1D and 2D homonuclear and heteronuclear experiments and pulse programs.

The Fourier 80 is routinely equipped with a pulsed gradient, which has been used in high-field NMR gradient spectroscopy for decades to obtain essentially artifact-free spectra. The optional, industry-standard PAL® sample changer can run up to 132 samples, including 12 reference samples, thereby dramatically increasing throughput.

The Fourier 80 allows any chemistry lab to utilize the power of NMR without the higher cost, space requirements, cryogen handling or expertise needed for mid- or high-field NMRs.

Bruker is also pleased to announce the addition of its newest supercon FT-NMR spectrometer, the AvanceCore. This streamlined two-channel 400 MHz NMR system offers high-quality NMR at an affordable price, making high-resolution, mid-field NMR more accessible. The AvanceCore leverages Bruker’s extensive NMR expertise and is designed for customers with limited budgets who nonetheless need the analytical power of a 400 MHz NMR instrument.

Lastly, with the recent acquisition of the Magnettech EPR business from Freiberg Instruments, Bruker can now offer high performance in a compact benchtop EPR system. Weighing only 45 kilograms, the Magnettech ESR 5000 can fit on a bench or in a fume hood, and can detect, quantify and characterize paramagnetic species, unpaired electrons, free radicals, reactive oxygen species and transition metal complexes.

Dr. Falko Busse, President of the Bruker BioSpin Group, commented: "With the Fourier 80, AvanceCore, and Magnettech ESR 5000, we now can offer high-quality magnetic resonance instruments to more labs and more researchers than ever before. We appreciate the support of the MR community and we are committed to continue to innovate with high-value chemistry and life science research and analytical solutions."

Please join Bruker during the ENC conference starting on March 26th at our virtual hub. Watch exclusive content relating to Bruker magnetic resonance products and hear from experts. Visitors can ask questions and interact with members of the Bruker NMR, EPR and MRI teams.

® PAL is a registered trademark of CTC Analytics AG

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Investor Contact:
Miroslava Minkova
Director of Investor Relations & Corporate Development
T: +1 (978) 663-3660, ext. 1479
E: Investor.Relations@bruker.com

Media Contact:
Thorsten Thiel, Ph.D.
VP of Group Marketing
Bruker BioSpin
T: +49 (721) 5161–6500
E: thorsten.thiel@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Summary
Bruker Makes Routine Magnetic Resonance Spectroscopy More Broadly Accessible for Chemical Analysis Outside Central Labs
Release Versions

Contacts

Investor Contact:
Miroslava Minkova
Director of Investor Relations & Corporate Development
T: +1 (978) 663-3660, ext. 1479
E: Investor.Relations@bruker.com

Media Contact:
Thorsten Thiel, Ph.D.
VP of Group Marketing
Bruker BioSpin
T: +49 (721) 5161–6500
E: thorsten.thiel@bruker.com

More News From Bruker Corporation

Chemspeed and SciY Announce Self‑Driving Laboratory Platform Integrating Automation, Analytics and AI Orchestration

BOSTON--(BUSINESS WIRE)--At SLAS2026, Chemspeed Technologies, a leader in the automation and digitalization of R&D and QC laboratories, and SciY, a leader in scientific and laboratory management software focused on lab standardization and AI-readiness, today introduce their open Self‑Driving Lab (SDL) platform. Their Self-Driving Lab platform is designed to accelerate research and development (R&D), quality control (QC) and chemical and biomolecular manufacturing workflows. The SDL enab...

Bruker Introduces iNTApharma™, a Label‑Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation today announced the launch of iNTApharma, a label‑free characterization platform that provides single‑particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston, iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native‑state assessment of bio-nanoparticl...

Bruker Announces Quarterly Preferred Stock Dividend

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR, BRKRP) today announced that its Board of Directors (“Board”) has approved payment of a quarterly cash dividend in the amount of $3.9844 per share on the Company’s 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock Dividend”). The Mandatory Convertible Preferred Stock Dividend will be paid on March 2, 2026 to stockholders of record as of February 15, 202...
Back to Newsroom